On January 26, 2026, PROLLENIUM Medical Technologies announced the appointment of Erick Brenner as chief executive officer. Brenner success Walter Geiger, interim CEO since April of last year who will return to his role as operating partner at majority shareholder ARCHIMED.
“PROLLENIUM has benefited from strong operational leadership over the past year, and we are grateful to Walter for his stewardship during a critical period,” said Justin Bateman, chair of the board of advisors. “Erick brings deep industry experience and a proven ability to scale global aesthetics platforms, which aligns well with the company’s long-term growth ambitions.”
Brenner most recently served as president of Galderma US, where he oversaw a $1.8 billion portfolio across injectable aesthetics, dermatologic skincare and therapeutic dermatology. He has more than 25 years of experience across pharmaceuticals, medical aesthetics and consumer skincare.
“PROLLENIUM has built a compelling platform by combining research and development, manufacturing and commercial execution under one roof,” Brenner said. “I look forward to working with the team to continue expanding the company’s global presence while maintaining a strong focus on quality, safety and clinical performance.”
